Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

30 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

Eligibility Breast Cancer NCT00897702

- 22.02.17 - 1 Formular, 2 Itemgruppen, 12 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00897702

Hypofractionated Radiotherapy in Prostate Cancer NCT01368055 - Eligibility Criteria

- 15.03.21 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Hypofractionated Proton Radiation Therapy for Low and Intermediate Risk Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01368055

Lung Cancer RADIATION THERAPY NCT00020709 - RADIATION THERAPY FORM LUNG CARCINOMA NCT00020709

- 08.05.15 - 1 Formular, 2 Itemgruppen, 42 Datenelemente, 1 Sprache
Itemgruppen: Header, TREATMENT INFORMATION
LUNG CARCINOMA RADIATION THERAPY FORM S0023: Combination Chemo Plus RT With or Without Gefitinib in Treating Patients With Unresectable Stage III NSCLC NCT00020709 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9E343E83-5FEB-119F-E034-080020C9C0E0

HistoScanning-based Brachytherapy in Prostate Cancer NCT01409876 - Eligibility Criteria

- 22.05.19 - 1 Formular, 2 Itemgruppen, 11 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Phase II trial looking at the feasibility of HistoScanning-based dose-painting image-guided interstitial brachytherapy in non-metastatic prostate cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01409876

SABR in High Risk Prostate Cancer (SATURN) NCT01953055 - Eligibility Criteria

- 22.05.19 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Phase II Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation for Patients With High Risk Prostate Cancer (SATURN); ODM derived from: https://clinicaltrials.gov/show/NCT01953055

Initial Follow-up Form Prostate Cancer (NCT00288080)

- 07.01.15 - 1 Formular, 7 Itemgruppen, 66 Datenelemente, 1 Sprache
Itemgruppen: Header, Vital Status, Progression, PROSTATE: PSA MEASUREMENTS, Treatment Schedule (LHRH Agonist), TREATMENT SCHEDULE (ORAL ANTIANDROGEN), Non-protocol Therapy
RTOG 0521 FO: Radiation Therapy Oncology Group Phase III Randomized Study of Localized, High-Risk Prostate Cancer Initial Follow-up Form Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer NCT00288080 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=0CB07BEA-FAB7-6032-E044-0003BA3F9857

Oral Topotecan as Radiosensitizing Agent in Patients with Rectal Cancer; NCT00158886 - Post RT/Prior to Surgery

- 19.08.19 - 1 Formular, 4 Itemgruppen, 14 Datenelemente, 1 Sprache
Itemgruppen: Administrative documentation, Serious Adverse Event, 12 lead ECG, Experimental drug, Compliance behavior
Study ID: 104864/517 Clinical Study ID: 104864/517 Study Title: A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158886 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Topotecan + Radiation therapy Trade Name: N/A Study Indication: Rectal Cancer, Carcinoma, Renal Cell

Prostate Cancer Radiation Therapy Calculation Form RTOG NCT00023829 - Radiation Therapy Calculation Form Prostate Cancer NCT00023829

- 20.05.15 - 1 Formular, 2 Itemgruppen, 27 Datenelemente, 1 Sprache
Itemgruppen: Header, Radiation therapy
T4 Radiation Therapy Oncology Group Protocol Calculation Form Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer NCT00023829 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A4E27DE7-685D-26F8-E034-080020C9C0E0

Gamma H2AX DNA Repair During Prostate Cancer Radiotherapy NCT01899391 - Eligibility Criteria

- 22.05.19 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Pilot Study of Gamma H2AX DNA Repair Foci Kinetics in Peripheral Blood Lymphocytes During Prostate Cancer Radiotherapy; ODM derived from: https://clinicaltrials.gov/show/NCT01899391

Breast Cancer Radiation Therapy Report NSABP B-36 NCT00087178 - Radiation Therapy Report Breast Cancer NCT00087178

- 20.05.15 - 1 Formular, 4 Itemgruppen, 17 Datenelemente, 1 Sprache
Itemgruppen: Header, Radiation therapy, Whole Breast Irradiation, Chest Wall Irradiation
NSABP Protocol B-36 Radiation Therapy Report Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer NCT00087178 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=C87B5190-AA07-59CE-E034-0003BA12F5E7

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Screening - Prior Ovarian Cancer Treatment; Laboratory Tests; Lesion Assessment Record

- 23.08.19 - 1 Formular, 13 Itemgruppen, 48 Datenelemente, 1 Sprache
Itemgruppen: Administrative, Prior Ovarian Cancer Treatment - Chemotherapy, Has the patient received radiotherapy?, Prior Ovarian Cancer Treatment - Radiotherapy , Has the patient received prior cancer-related surgery?, Prior Ovarian Cancer Treatment - Surgical Treatment , Has the patient received other cancer-related treatments?, Other Cancer Related Treatments, Laboratory Tests (within 7 days prior to Day 1) - Haematology, Laboratory Tests (within 7 days prior to Day 1) - Haematology , Laboratory Tests (within 7 days prior to Day 1) - Chemistry, Laboratory Tests (within 7 days prior to Day 1) - Chemistry , Lesion Assessment Record
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer

Breast Cancer NCT01272037 Treatment - S1007 Radiation Therapy Form (S1007RAD) - 3139641v1.0 - S1007 Radiation Therapy Form (S1007RAD)

- 09.01.15 - 1 Formular, 6 Itemgruppen, 30 Datenelemente, 1 Sprache
Itemgruppen: Header Module, Radiation Therapy, Site Irradiated, Targeted Regions of Treatment, Partial Breast Irradiation Method, Comments
S1007 Radiation Therapy Form (S1007RAD) Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=90C9DFFB-2367-84DB-E040-BB89AD437DC2

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video